SCHEMBL4351887

SCHEMBL4351887

COc1ccc(-c2ccc(CN3CC(Oc4ccc(-c5ccc(S(C)(=O)=O)nc5)cc4)C3)cn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.45
MCHR1 Q99705 7/20 0.44
KCNH2 Q12809 5/20 0.44
CYP11B1 P15538 2/20 0.44
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
PDE10A Q9Y233 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
ACACB O00763 1/20 0.37
NAAA Q02083 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348326 0.92 KCNH2 (0.50) MCHR1KCNH2PDE10AHRH3ACACB
SCHEMBL3892630 0.89 NAAA (0.43) KCNJ1MCHR1KCNH2CYP11B1NAAA
SCHEMBL4533849 0.86 MCHR1 (0.42) MCHR1KCNH2PDE10AHRH3ACACB
SCHEMBL4350493 0.85 MMP1 (0.43) KCNJ1MCHR1KCNH2GPR119MLNR
SCHEMBL14403832 0.84 KCNH2 (0.41) KCNJ1MCHR1KCNH2HRH3PRKAA2
SCHEMBL4345654 0.84 RORC (0.43) KCNJ1MCHR1KCNH2HRH3ACACB
SCHEMBL4349396 0.84 PRKAA2 (0.45) MCHR1KCNH2PRKAA2
SCHEMBL4353675 0.83 RORC (0.44) MCHR1KCNH2HRH3ACACBGPR119
SCHEMBL13269645 0.82 KCNH2 (0.40) KCNJ1MCHR1KCNH2HRH3ACACB
SCHEMBL2888033 0.82 MCHR1 (0.42) KCNJ1MCHR1KCNH2HRH3ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP claimed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US claimed
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
WO-2007116230-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists GPR119, GPR39, GIPR KCNJ1 742/4885MCHR1 132/4885KCNH2 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.